Afala, tablets 100 pcs

Pharmacodynamics

It reduces inflammation and edema in the prostate, normalizes its functional state. It improves urodynamics, decreases the volume of residual urine, normalizes the tone of the lower parts of the urinary tract, reduces dysuric disorders.

Pharmacokinetics

The sensitivity of modern physico-chemical analysis methods (gas-liquid chromatography, high performance liquid chromatography, chromato-mass spectrometry) does not allow evaluating the content of ultra-low doses of antibodies in biological fluids, organs and tissues, which makes it technically impossible to study the pharmacokinetics of the drug Afala.

Indications

Afala® is indicated for use in adults.
Benign prostatic hyperplasia stages I and II.
Chronic abacterial prostatitis – as an anti-inflammatory and analgesic.
Dysuric disorders (frequent urge to urinate, including at night, difficulty urinating, pain or discomfort in the perineal area) accompanying benign prostatic hyperplasia stages I and II and chronic abacterial prostatitis.

Pharmacological effect

Pharmacotherapeutic group

Benign prostate hyperplasia treatment.

ATX code

G04СX.

Pharmacological properties

Pharmacodynamics

Reduces inflammation and swelling in the prostate gland, normalizes its functional state. Improves urodynamics, reduces the volume of residual urine, normalizes the tone of the lower urinary tract, and helps reduce dysuric disorders.

Pharmacokinetics

The sensitivity of modern physicochemical methods of analysis (gas-liquid chromatography, high-performance liquid chromatography, gas chromatography-mass spectrometry) does not allow assessing the content of the active substance in biological fluids, organs and tissues, which makes it technically impossible to study the pharmacokinetics of the drug Afala®.

Special instructions

If you have an intolerance to certain sugars, consult your doctor before taking this drug.

Impact on the ability to drive vehicles and machinery
The drug Afala® does not affect the ability to drive vehicles and other potentially dangerous mechanisms.

Composition

Active ingredient:

affinity purified antibodies to prostate-specific antigen – 10,000 EMD*.

Excipients: lactose monohydrate, microcrystalline cellulose, magnesium stearate.

* EMD – units of modifying action.

Pregnancy

Afala® is not intended for use in women.

Contraindications

Increased individual sensitivity to the components of the drug. Not recommended for use in patients under 18 years of age due to insufficient data on efficacy and safety for this age.
Lactase deficiency, hereditary galactose intolerance, glucose-galactose malabsorption.

Side Effects

Individual hypersensitivity reactions to the components of the drug are possible.

Interaction

No cases of incompatibility with other drugs have been reported to date.

Overdose

In case of overdose, dyspepsia may occur due to the excipients included in the drug.

Storage conditions

At a temperature not exceeding 25 °C.
Keep out of the reach of children.
During the period of use of the drug, store the blister pack in a cardboard box provided by the manufacturer.

Shelf life

3 years. Do not use after expiration date.

Manufacturer

Materia Medica Holding, Russia